Cargando…
Development of ST-246® for Treatment of Poxvirus Infections
ST-246 (Tecovirimat) is a small synthetic antiviral compound being developed to treat pathogenic orthopoxvirus infections of humans. The compound was discovered as part of a high throughput screen designed to identify inhibitors of vaccinia virus-induced cytopathic effects. The antiviral activity is...
Autores principales: | Jordan, Robert, Leeds, Janet M., Tyavanagimatt, Shanthakumar, Hruby, Dennis E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185582/ https://www.ncbi.nlm.nih.gov/pubmed/21994624 http://dx.doi.org/10.3390/v2112409 |
Ejemplares similares
-
Pharmacokinetics and Interspecies Allometric Scaling of ST-246, an Oral Antiviral Therapeutic for Treatment of Orthopoxvirus Infection
por: Amantana, Adams, et al.
Publicado: (2013) -
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination
por: Grosenbach, Douglas W., et al.
Publicado: (2008) -
Comparison of the Safety and Pharmacokinetics of ST-246® after IV Infusion or Oral Administration in Mice, Rabbits and Monkeys
por: Chen, Yali, et al.
Publicado: (2011) -
Development of CMX001 for the Treatment of Poxvirus Infections
por: Lanier, Randall, et al.
Publicado: (2010) -
Cidofovir in the treatment of poxvirus infections
por: De Clercq, Erik
Publicado: (2002)